OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News Eli Lilly and Co. could face generic competition on its antidepressant drug Prozac as early as August 3, 2001 following a federal appeals court ruling in July 2001, that it would not reconsider an earlier ruling that found the drug company's 2003 patent invalid. Lilly had hoped to extend its patent on the drug through 2003, and now plans to appeal the decision to the U.S. Supreme Court. "We still feel it's very valid, but at this stage of the appeal, we realize that it . . .

OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News Eli Lilly and Co. could face generic competition on its antidepressant drug Prozac as early as August 3, 2001 following a federal appeals court ruling in July 2001, that it would not reconsider an earlier ruling that found the drug company's 2003 patent invalid. Lilly had hoped to extend its patent on the drug through 2003, and now plans to appeal the decision to the U.S. Supreme Court. "We still feel it's very valid, but at this stage of the appeal, we realize that it . . .